Request Demo
NTC, BACKED BY WISE EQUITY, COMPLETES THE ACQUISITION OF PHARMATHEN'S OPHTHALMOLOGY BUSINESS
10 Dec 2025
Acquisition
Supported by Wise Equity, NTC expands its portfolio in the glaucoma segment strengthening its competitive position in the European eye care market.
This transaction allows NTC to reach about €100 million of revenues, of which more than 80% in ophthalmology, and to further expand its international presence by also including the U.S. market.
MILAN, Dec. 10, 2025 /PRNewswire/ --
NTC S.r.l., one of the leading Italian pharmaceutical companies focused on ophthalmology, along with its main shareholder
Wise Equity, announce the completion of the acquisition of
Pharmathen's ophthalmology business. The acquisition adds to NTC a consolidated and global portfolio of glaucoma treatments, manufactured in various European and U.S. third-party facilities and commercialized through a well-established B2B network across Europe and selected international markets.
Continue Reading
Riccardo Carbucicchio
Stefano Ghetti
Ascanio Recchi
Pharmathen Logo
Wise Logo
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.